UA138153U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes clinical examination and radiography. Additionally, in the patient's serum determine the polymorphism of the gene for methylenetetrahydrofolate reductase (MTHFR C677T), the content of thrombomodulin, folic acid, oxyproline, homocysteine and homozygous carrier 677-TT and levels of thrombomolutulin> 5 ml / 6 ml / 6 μmol / l, homocysteine> 20 μmol / l predict the development of osteoarthritis.

Description

A useful model belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in the diagnosis of the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (Okorokov

A.N. Diagnosis of diseases of internal organs. - M., 2001. - T. 2. - E. 186-196). The disadvantage of these methods is the inability to predict the dynamics of the process in the early subclinical stages, the inability to prevent its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that, in addition to clinical examination and radiography, according to a useful model, the polymorphism of the methylenetetrahydrofolate reductase gene (MTNEV C677T), the content of thrombomodulin, folic acid, oxyproline, homocysteine, and in the case of homozygous carrier 677-TT, the content of thrombomodulin are determined in the patient's blood serum "5 ng/ml, folic acid "6 ng/ml, oxyproline 215 μmol/l, homocysteine 220 μmol/l predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, an X-ray is taken, and the MTNEV C677T gene polymorphism is determined. The content of thrombomodulin, folic acid, oxyproline, and homocysteine is determined by the immunoenzymatic method. With homozygous carrier 677-

TT, levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, oxyproline "15 μmol/l, homocysteine 220 μmol/l predict the development of osteoarthritis.

A specific example of using the method

Patient G., 64 years old, was hospitalized in the clinic due to pain syndrome in the left knee joint. Examined, x-ray taken. No signs of osteoarthritis were found. Polymorphism of MTNEV C677T gene was determined in blood serum. The content of thrombomodulin, folic acid, oxyproline, and homocysteine was determined by immunoenzymatic method. Homozygous carrier 677-TT was established. Levels of thrombomodulin - 13 ng/ml, folic acid - 3.7 ng/ml, oxyproline - 26 μmol/l, homocysteine - 32 μmol/l. The development of osteoarthritis was diagnosed.

After 13 months, X-rays revealed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that, in addition, in the patient's blood serum, the polymorphism of the methylenetetrahydrofolate reductase gene (MTNEV C677T), the content of thrombomodulin, folic acid, oxyproline, homocysteine, and in the case of homozygous carrier 677-TT and thrombomodulin levels are determined 25 ng/ml, folic acid "b ng/ml, oxyproline 215 μmol/l, homocysteine 220 μmol/l predict the development of osteoarthritis.